Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobeglitazone add-on to Metformin and Empagliflozin in T2DM
NCT03739125Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing CKD-501 with Placebo (2 arms). Primary endpoint: Glycosylated Hemoglobin at 24 weeks. Started Nov 2017; status: completed.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03739125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739125.